A:

While biotechnology and pharmaceutical companies both produce medicine, biotechnology companies' drugs have a biological basis, while those of pharmaceutical companies  have a chemical basis. Biotechnology companies use live organisms or their products, such as bacteria or enzymes, to manufacture their medicines. Conversely, pharmaceutical companies use generally artificial  materials to create drugs.

Biotechnology firms also have more applications than pharmaceutical companies. For example, biotechnology companies have developed versions of crops without specific food allergens, crops that require fewer pesticides and crops with a more complete nutrient profile. While there is some overlap between biotechnology and pharmaceutical companies in terms of research, manufacturing and distributing drugs, biotechnology's scope is much greater.

There is also a substantial difference in operating costs, especially the cost of research and development. Biotechnology companies have much higher costs due to their focus on research and development (as opposed to manufacturing with pharmaceutical companies) and the length of time and difficulty in testing and creating new products.

The discrepancy in the cost and length of time required to manufacture a new product has led to biotechnology products holding their patents for much longer than pharmaceutical companies. Where pharmaceutical companies generally hold the exclusive rights to manufacture and distribute their drugs for five years, biotechnology companies have their patents for 12 years.

All of this leads to very volatile profits for biotechnology companies. Many operate at a loss for many years until a highly profitable substance is manufactured – but when it does, their earnings can be even greater than those of pharmaceutical companies. Conversely, pharmaceutical firms' profits, and therefore their stock prices, tend to fluctuate less.

RELATED FAQS
  1. What are examples of major companies in the drugs sector?

    Identify the major players in the drugs sector, which include many established pharmaceutical companies that have delved ... Read Answer >>
  2. What annual return could an investor expect on average from the drug sector?

    Learn which annual average returns the drugs manufacturing sector and its industries can generate for investors based on ... Read Answer >>
  3. Why should an investor include an allocation to the drugs sector in their portfolio?

    Learn why investors should consider allocating assets to the drug sector as part of a diversified investment portfolio and ... Read Answer >>
  4. What options strategies are best suited for investing in the drugs sector?

    Learn how the covered call strategy works well with the pharmaceuticals segment of the drugs sector and how the long straddle ... Read Answer >>
  5. What percentage of a diversified portfolio should be invested in the drugs sector?

    Learn how to determine how much of a diversified portfolio should be devoted to the pharmaceutical and biotechnology segments ... Read Answer >>
  6. What metrics are often used to evaluate companies in the drugs sector?

    Learn about some of the equity evaluation metrics that are most frequently used for examining companies in the pharmaceutical ... Read Answer >>
Related Articles
  1. Investing

    IBB: iShares NASDAQ Biotechnology ETF

    Learn about the iShares Nasdaq Biotechnology exchange-traded fund, which offers one of the most diversified ways of investing in the biotechnology sector.
  2. Investing

    A Quick Guide To Healthcare ETFs

    The healthcare industry offers a broad variety of sector ETFs but it’s difficult to avoid exposure to pharmaceuticals and biotechnology .
  3. Financial Advisor

    Investing In Biotech: Is It Worth The Risk?

    Investors shunned biotech after a weak start in 2014. Now that a comeback is in the works, should they reconsider?
  4. Investing

    BBP: BioShares Biotechnology Products ETF

    Learn more about the BioShares Biotechnology Products fund, an exchange-traded fund that is focused on producers of FDA-approved drugs.
  5. Investing

    UBIO: ProShares UltraPro Nasdaq Biotech ETF

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  6. Investing

    A Primer On The Biotech Sector

    Investing in the biotech sector can involve both huge losses and major gains.
  7. Investing

    Are Bears About to Burst the Biotech Bubble? (IBB, BIB)

    The recent biotech rally has richly rewarded many investors. So will the fortunes be soon swept away?
  8. Investing

    Active Traders Turn Bullish on Biotech

    The recent price activity of two key ETFs suggests that the biotech sector is poised for a comeback.
  9. Insurance

    Big Pharma: Will Price Pressure Happen No Matter What?

    Watch out for a possible decline in pharmaceutical stock prices, thanks to a renewed debate about the role of government policy and macroeconomic headwinds.
RELATED TERMS
  1. Biotechnology Industry ETF

    An exchange-traded fund that invests specifically in the rapidly ...
  2. Stock And Warrant Off-Balance Sheet R&D - SWORD

    A financing option developed to help biotechnology companies ...
  3. Intellectual Property Rights (Biotechnology)

    In health care, intellectual property rights give their owners ...
  4. Medical Patent

    A legal protection against market competition that a government ...
  5. Healthcare Sector

    The healthcare sector consists of companies that provide medical ...
  6. Patent Cliff

    A colloquialism to denote the potential sharp decline in revenues ...
Hot Definitions
  1. Net Present Value - NPV

    Net Present Value (NPV) is the difference between the present value of cash inflows and the present value of cash outflows ...
  2. Return On Equity - ROE

    The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability ...
  3. Bond

    A bond is a fixed income investment in which an investor loans money to an entity (corporate or governmental) that borrows ...
  4. Whole Life Insurance Policy

    A life insurance contract with level premiums that has both an insurance and an investment component. The insurance component ...
  5. Compound Annual Growth Rate - CAGR

    The Compound Annual Growth Rate (CAGR) is the mean annual growth rate of an investment over a specified period of time longer ...
  6. Capital Asset Pricing Model - CAPM

    A model that describes the relationship between risk and expected return and that is used in the pricing of risky securities. ...
Trading Center